Lifesci Capital Has Strong Forecast for Immunome Q2 Earnings

Immunome, Inc. (NASDAQ:IMNM - Free Report) - Equities research analysts at Lifesci Capital raised their Q2 2025 earnings estimates for shares of Immunome in a report issued on Tuesday, June 3rd. Lifesci Capital analyst C. Zhu now expects that the company will post earnings per share of ($0.55) for the quarter, up from their prior estimate of ($0.61). Lifesci Capital currently has a "Outperform" rating and a $20.00 target price on the stock. The consensus estimate for Immunome's current full-year earnings is ($2.21) per share. Lifesci Capital also issued estimates for Immunome's Q3 2025 earnings at ($0.60) EPS, Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.34) EPS, Q1 2026 earnings at ($0.75) EPS, Q2 2026 earnings at ($0.75) EPS, Q3 2026 earnings at ($0.62) EPS, Q4 2026 earnings at ($0.58) EPS and FY2026 earnings at ($2.70) EPS.

Immunome (NASDAQ:IMNM - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.52) EPS for the quarter, topping analysts' consensus estimates of ($0.66) by $0.14. The company had revenue of $2.93 million during the quarter, compared to the consensus estimate of $0.46 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%.

A number of other equities analysts also recently commented on the stock. Wedbush reaffirmed an "outperform" rating and set a $21.00 price objective (down from $33.00) on shares of Immunome in a report on Tuesday, May 13th. Guggenheim dropped their target price on shares of Immunome from $35.00 to $25.00 and set a "buy" rating for the company in a research report on Thursday, March 20th. Wall Street Zen upgraded shares of Immunome from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Lake Street Capital initiated coverage on shares of Immunome in a research report on Wednesday, April 2nd. They set a "buy" rating and a $23.00 target price for the company. Finally, Stephens reiterated an "overweight" rating and set a $30.00 target price on shares of Immunome in a research report on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $23.33.

Immunome Stock Performance

Shares of NASDAQ:IMNM traded up $0.01 during midday trading on Thursday, reaching $9.13. 1,228,054 shares of the company's stock were exchanged, compared to its average volume of 920,741. The company's 50 day simple moving average is $7.88 and its two-hundred day simple moving average is $9.50. The firm has a market capitalization of $794.42 million, a PE ratio of -1.13 and a beta of 1.94. Immunome has a 12 month low of $5.15 and a 12 month high of $16.81.

Institutional Investors Weigh In On Immunome

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IMNM. BNP Paribas Financial Markets bought a new position in shares of Immunome in the 4th quarter valued at about $70,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Immunome during the 4th quarter worth approximately $75,000. AlphaQuest LLC grew its position in shares of Immunome by 786,700.0% during the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock worth $84,000 after buying an additional 7,867 shares during the period. Tower Research Capital LLC TRC grew its position in shares of Immunome by 482.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock worth $91,000 after buying an additional 7,129 shares during the period. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Immunome during the 4th quarter worth approximately $95,000. Institutional investors and hedge funds own 44.58% of the company's stock.

Insider Buying and Selling at Immunome

In related news, CTO Philip Tsai acquired 12,300 shares of the stock in a transaction on Monday, March 24th. The stock was purchased at an average price of $8.42 per share, for a total transaction of $103,566.00. Following the transaction, the chief technology officer now owns 33,300 shares of the company's stock, valued at $280,386. The trade was a 58.57% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Clay B. Siegall acquired 137,100 shares of the stock in a transaction on Wednesday, March 26th. The stock was bought at an average price of $7.29 per share, with a total value of $999,459.00. Following the transaction, the chief executive officer now directly owns 806,736 shares in the company, valued at approximately $5,881,105.44. This represents a 20.47% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 161,400 shares of company stock worth $1,207,395. 8.60% of the stock is currently owned by corporate insiders.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.